When Will This Obesity Drug Launch?

Hurry up and wait.

That's been the story of Arena Pharmaceuticals' (NASDAQ: ARNA  ) Belviq. The obesity drug was approved back in June, but the biotech's partner Eisai  (NASDAQOTH: ESALY  ) couldn't launch the drug because it had to wait for the Drug Enforcement Agency to determine how likely the drug is to be abused.

The DEA agreed with the Food and Drug Administration and recommended a Schedule IV designation. But more waiting ensued as the DEA took the standard 30-days of public comments.

The biotech held its fourth-quarter conference call Monday, but investors are still left waiting with no mention of an exact date for when Belviq will be launched. The public comment period ended in January, but the DEA is still reading the comments and hasn't issued its final ruling.

Even after the final DEA ruling, investors could still be left waiting. Technically the DEA can ask for a 30-day waiting period after the final scheduling, although Eisai has asked for that to be waived.

How much the delay helps VIVUS' (NASDAQ: VVUS  ) Qsymia is debatable. Sure, the biotech has gotten a few months free of competition from other new obesity treatments. But VIVUS may actually benefit from Eisai's promotion to doctors, which need to be educated about the potential health benefits of taking obesity drugs. The drugs may not overlap much either; with its more severe side effect profile, Qsymia is likely to be prescribed to morbidly obese patients while Belviq finds a niche in patients that want a safer medication albeit with less weight loss.

You could argue that the third obesity drug player, Orexigen (NASDAQ: OREX  ) , benefits since it's behind Arena, but probably not by much. The biotech hasn't even resubmitted its application for Contrave. It could take six months after that to get approved. By that time, Qsymia and Belviq will be well into their launches; I doubt the delay will matter that much.

While you're waiting for the launch to finally come, check out the Fool's comprehensive look at Arena, including its massive opportunity, potential pitfalls, and key reasons to both buy and sell. To find out more about Arena -- and get a full year of updates -- click here to access your report today.

 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2449523, ~/Articles/ArticleHandler.aspx, 10/22/2014 10:32:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement